Anchor Bill Ritter Shares Alzheimer's Diagnosis
The veteran broadcaster aired a special on his health journey after announcing a diagnosis of early-stage Alzheimer's disease.
Updated on Oct. 21, 2026 in Alzheimer’s
Longtime New York news anchor Bill Ritter, 76, revealed his early-stage Alzheimer's diagnosis on June 12, 2026. Following the announcement, he produced and aired a half-hour television special on WABC-TV titled Living With Alzheimer's.
Why it matters
By sharing his personal experience, Ritter aims to shed light on the realities of living with Alzheimer's disease. He intends to continue his work in local news for as long as his health remains stable.
Bill Ritter served in local television for 28 years prior to this disclosure. His half-hour special featured expert insights on FDA-approved treatments like lecanemab and donanemab, which clinical trials show slow cognitive decline.
The players
Bill Ritter
Bill Ritter is a veteran news anchor who has worked in New York local television for 28 years.
WABC-TV
WABC-TV is a local television station in New York City that serves as the flagship station for the ABC network.
The details
The program features interviews with medical researchers and other individuals currently navigating their own Alzheimer's diagnoses. Ritter hopes the project provides viewers with a better understanding of the disease as new generations of treatments are developed.
Timeline
June 12, 2026: Bill Ritter announced his Alzheimer's diagnosis on a newscast.
October 15, 2026: The special program aired on WABC-TV.
Health Landscape
This public disclosure follows the FDA approval of lecanemab and donanemab, shifting the medical discourse from purely palliative care to treatments that actively slow cognitive decline. These advancements mark a significant evolution in how society and patients approach early-stage Alzheimer's diagnoses.
Ritter's special highlights that early detection and awareness of available treatments can fundamentally change a patient's long-term care plan. Viewers should consult their physicians to discuss current diagnostic tools and FDA-approved therapies if they have concerns about cognitive health.
The takeaway
Ongoing research into new Alzheimer's treatments suggests that early intervention remains critical for patients. Individuals should prioritize open conversations with medical professionals to navigate the complexities of cognitive health.
Further reading
For more information on the latest disease management resources, visit Alzheimer’s.
Source note: This article includes information reported by MediaPost.
